Rosen Law Firm files Beta Bionics investor suit over iLet device claims
Rosen Law Firm says investors who bought Beta Bionics common stock during a stated class period may seek lead-plaintiff status in a securities case tied to the company’s iLet insulin pump.
Rosen Law Firm says it has filed a securities class action on behalf of buyers of Beta Bionics Inc. common stock, trading under NASDAQ: BBNX, for purchases made between July 30, 2025, and Feb. 24, 2026.
The notice, published Sept. 8, 2026, says the case concerns Beta Bionics’ iLet Bionic Pancreas insulin pump, an automated insulin delivery system for diabetes. Rosen says investors who want to serve as lead plaintiff must ask the court by Nov. 3, 2026.
According to the notice, the lawsuit alleges that the Food and Drug Administration raised serious issues about the iLet device, including malfunctioning and dosing patients with dangerously high levels of insulin. Rosen says those allegations led to hypoglycemic events.
The notice also alleges that complaints back-filed with the FDA numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention. It says Beta Bionics failed to implement meaningful corrective actions.
The PR Newswire notice does not include a response from Beta Bionics. It identifies Phillip Kim, Esq., as a contact for Rosen Law Firm and lists the firm’s New York address and toll-free number.
Rosen says the class action has already been filed. The notice says investors who believe they fall within the class period can seek lead-plaintiff status in federal court before the Nov. 3 deadline.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()